Vizsgálati helyszín
Moffit Cancer Center
Tampa, Florida 33612, Egyesült ÁllamokMég nincs intézményhez kötve
- 18futó vizsgálat
- 1lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 19 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis8 vizsgálat
- 1. fázis7 vizsgálat
- 1/2. fázis2 vizsgálat
- 2. fázis1 vizsgálat
- Állapot
- Toboroz8 vizsgálat
- Fut, nem toboroz5 vizsgálat
- Még nem toboroz5 vizsgálat
- Lezárult1 vizsgálat
- Fő szponzor
- Janssen Research & Development, LLC3 vizsgálat
- Celyad Oncology SA2 vizsgálat
- Institut de Recherches Internationales Servier2 vizsgálat
- BioNTech SE1 vizsgálat
- CG Oncology, Inc.1 vizsgálat
- és még 10
Futó vizsgálatok
Még nem toboroz
Modifying Diet to Improve Gut Microbiome
NCT03924778· H. Lee Moffitt Cancer Center and Research Institute· Forrás
Contact: Tiffany Carson, PhD
Toboroz
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
NCT07623161· 3. fázis· Takeda· Forrás
Contact: Andrew Kuykendall (principal investigator)
Toboroz
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
NCT07258511· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma
NCT07219212· 1. fázis· Johnson & Johnson Enterprise Innovation Inc.· Forrás
Toboroz
Neoadjuvant Darovasertib in Primary Uveal Melanoma
NCT07015190· 3. fázis· IDEAYA Biosciences· Forrás
Contact: Nikhil Khushalani, MD, Principal Investigator
Toboroz
Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.
NCT07217704· 3. fázis· SOFIE· Forrás
Contact: Jacqueline Guillermo Adams
Toboroz
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy
NCT06745908· 3. fázis· ImmunityBio, Inc.· Forrás
Contact: Erika Gonzalez
Toboroz
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
NCT07111520· 1/2. fázis· BioNTech SE· Forrás
Toboroz
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT06852222· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
NCT06150157· 1. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma
NCT05257083· 3. fázis· Stichting European Myeloma Network· Forrás
Toboroz
Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer
NCT04991948· 1. fázis· Celyad Oncology SA· Forrás
Contact: Kim Dae Won, MD
Fut, nem toboroz
A Study to Evaluate the Long-term Safety of Patients With Advanced Lymphoid Leukemia Who Have Been Previously Administered With UCART19
NCT02735083· 1. fázis· Institut de Recherches Internationales Servier· Forrás
Fut, nem toboroz
Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
NCT04452591· 3. fázis· CG Oncology, Inc.· Forrás
Toboroz
Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
NCT04317534· 2. fázis· Greg Durm, MD· Forrás
Contact: Mari Hardy
Fut, nem toboroz
DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer
NCT04042701· 1. fázis· Daiichi Sankyo· Forrás
Toboroz
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
NCT03692429· 1. fázis· Celyad Oncology SA· Forrás
Contact: Kim Dae Won, MD
Toboroz
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
NCT02074839· 1. fázis· Institut de Recherches Internationales Servier· Forrás
Contact: Institut de Recherches Internationales Servier Clinical Studies Department
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Hibát jelzek